Published in Eur J Endocrinol on September 01, 2007
Obestatin as a regulator of adipocyte metabolism and adipogenesis. J Cell Mol Med (2011) 1.01
Associations between macronutrient intake and self-reported appetite and fasting levels of appetite hormones: results from the Optimal Macronutrient Intake Trial to Prevent Heart Disease. Am J Epidemiol (2009) 0.92
Characteristics associated with fasting appetite hormones (obestatin, ghrelin, and leptin). Obesity (Silver Spring) (2008) 0.91
Effects of circuit resistance training intensity on the plasma ghrelin to obestatin ratios in healthy young women. Int J Endocrinol Metab (2012) 0.83
Eradication of Helicobacter pylori increases ghrelin mRNA expression in the gastric mucosa. J Korean Med Sci (2010) 0.83
Impact of sustained weight loss achieved through Roux-en-Y gastric bypass or a lifestyle intervention on ghrelin, obestatin, and ghrelin/obestatin ratio in morbidly obese patients. Obes Surg (2011) 0.79
Maternal High-Fat Diet during Pregnancy and Lactation Influences Obestatin and Ghrelin Concentrations in Milk and Plasma of Wistar Rat Dams and Their Offspring. Int J Endocrinol (2016) 0.78
Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes. Br J Pharmacol (2016) 0.75
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 3.62
The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev (2005) 2.90
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2013) 2.43
Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2015) 2.05
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci (2006) 1.53
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Obesity and reproductive disorders in women. Hum Reprod Update (2003) 1.45
Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril (2008) 1.44
CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab (2010) 1.33
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2004) 1.29
Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology (2006) 1.27
Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes (2008) 1.25
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res (2006) 1.24
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab (2006) 1.19
Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol (2009) 1.18
Stress-related development of obesity and cortisol in women. Obesity (Silver Spring) (2009) 1.14
Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes (2004) 1.14
Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep (2009) 1.13
The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol (2010) 1.12
Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med (2011) 1.07
Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. Steroids (2010) 1.06
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol (2007) 1.02
Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol (Oxf) (2008) 1.01
Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes (2010) 0.99
Comment: response of the hypothalamic-pituitary-adrenocortical axis to high-protein/fat and high-carbohydrate meals in women with different obesity phenotypes. J Clin Endocrinol Metab (2002) 0.98
Ghrelin as a potential anti-obesity target. Curr Pharm Des (2003) 0.98
Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. J Clin Endocrinol Metab (2014) 0.97
The endocannabinoid system and the treatment of obesity. Ann Med (2005) 0.97
The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. PLoS One (2013) 0.96
Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB₁ receptor blockade. Proc Natl Acad Sci U S A (2013) 0.96
Cortisol, energy intake, and food frequency in overweight/obese women. Nutrition (2010) 0.96
Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab (2012) 0.96
Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol (2012) 0.96
Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity. Obesity (Silver Spring) (2006) 0.95
Here, there and everywhere: the endocannabinoid system. J Neuroendocrinol (2008) 0.95
Autonomic disturbances in narcolepsy. Sleep Med Rev (2010) 0.95
Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res (2011) 0.94
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 0.93
Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. Otolaryngol Head Neck Surg (2007) 0.93
Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab (2010) 0.93
Predictors of weight loss and maintenance in patients treated with antiobesity drugs. Diabetes Metab Syndr Obes (2011) 0.92
High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep (2013) 0.92
Central effects of the somatotropic system. Eur J Endocrinol (2003) 0.92
Plasma antioxidant enzymes and clastogenic factors as possible biomarkers of colorectal cancer risk. Mutat Res (2011) 0.91
Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol (2010) 0.89
Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2013) 0.89
Leucine supplementation protects from insulin resistance by regulating adiposity levels. PLoS One (2013) 0.89
Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab (2013) 0.89
[Pharmacological therapy of obesity]. G Ital Cardiol (Rome) (2008) 0.88
Active and total ghrelin concentrations in the newborn. J Pediatr Endocrinol Metab (2005) 0.88
Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab (2002) 0.88
Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther (2011) 0.87
Ghrelin and reproductive disorders. Mol Cell Endocrinol (2011) 0.87
Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes (2012) 0.87
In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. J Clin Endocrinol Metab (2003) 0.87
Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet (2005) 0.87
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur J Endocrinol (2011) 0.87
Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab (2003) 0.86
Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum Reprod (2012) 0.85
Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol (2010) 0.85
Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis. Clin Endocrinol (Oxf) (2007) 0.84